Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | RINGSIDE: data from the safety analysis of varegacestat in desmoid tumors

Piotr Rutkowski, MD, PhD, Curie National Research Institute, Warsaw, Poland, discusses a detailed safety analysis from the Phase III RINGSIDE (NCT04871282) trial of once-daily varegacestat, a gamma-secretase inhibitor, versus placebo in adults with progressing desmoid tumors. Adverse events, most commonly diarrhea, fatigue, rash, and nausea, were more frequent with varegacestat, alongside electrolyte abnormalities and ovarian toxicity in premenopausal women that resolved in some cases. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

RINGSIDE trial, it was placebo-controlled, face-free trial, looking at the efficacy of varegacestat. Varegacestat is gamma secretase inhibitor used in the initial dose, 1 .2mg, in patients with progressing, measurable, symptomatic desmoid tumors...
RINGSIDE trial, it was placebo-controlled, face-free trial, looking at the efficacy of varegacestat. Varegacestat is gamma secretase inhibitor used in the initial dose, 1 .2mg, in patients with progressing, measurable, symptomatic desmoid tumors. And it showed very meaningful responses. PFS, after two years, was at the level of 89%. So it’s super good. The relative decrease of the chance of the progression was more than 80 % as compared to placebo. And what is also important, it was super good for patients’ feeling, because the quality of life was better, and also the decrease in the pain, which was one of the most important symptoms declared by the patients. So generally, the clinical activity is very high for this drug. In terms of the toxicity, first of all, there are some common types of the toxicities related to gamma secretase inhibitors. So fatigue, skin lesions, diarrhea, and also some laboratory abnormalities. And for women in reproductive… age, one of the problems is ovarian dysfunction. And it happened, this last part happened in about 57 % of patients. However, this patient who stopped the treatment was clearly reversible. So it’s good news, because we have amenorrhea, but probably it is not until the end of the life if we stop the treatment. With gamma secretase inhibitor Varegacestat needed the dose reduction in about 80 % of cases. However, majority of the patients stayed on one of the two doses, which could be possible to reduce. And only 20 % finally discontinued the treatment due to toxicity. So generally, adverse events are… common, but manageable, usually with dose reduction and not life-threatening at all.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.